All In Biotech

Drug Trial Radar · NCT02706886

Study of Lumasiran in Healthy Adults and Patients With Primary Hyperoxaluria Type 1

A Phase 1/2, Single-Blind, Placebo-Controlled, Single and Multiple Ascending Dose Safety, Tolerability, Pharmacokinetic and Pharmacodynamics Study of Subcutaneously Administered ALN-GO1 in Healthy Adult Subjects, and Patients With Primary Hyperoxaluria Type 1

Last checked: Nov 20, 2026Latest source record: Jan 30, 2020 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedResults posted on the registry

Status

Completed

Enrollment

52

Actual

Start

Mar 8, 2016

Primary completion

Jan 23, 2019

Study completion Jan 23, 2019

Sponsor

Lead sponsor
Alnylam PharmaceuticalsAlnylam Pharmaceuticals (ALNY)
Sponsor type
Industry
First posted
Mar 11, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Single (participant)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 6 years, up to 64 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of single-ascending doses (SAD) and multiple-ascending doses (MAD) of lumasiran in healthy adult volunteers and subjects with primary hyperoxaluria type 1 (PH1). In Part A, single ascending dose (SAD) part, healthy adults were dosed with lumasiran or placebo once. In Part B, multiple ascending doses (MAD) part, patients with primary hyperoxaluria type 1 (PH1) were dosed with lumasiran or placebo. All patients that initially received placebo received lumasiran after completing placebo dosing.

Conditions

  • Primary Hyperoxaluria Type 1 (PH1)

Interventions

  • LumasiranDrug

    Lumasiran will be administered SC once in Part A. In Part B lumasiran will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).

  • PlaceboDrug

    Matching placebo (sterile saline: 0.9% sodium chloride \[NaCl\]) will be administered SC once in Part A. In Part B matching placebo will be administered SC qM (Days 1, 29 and 57) or q3M (Days 1 and 85).

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Number of Participants With Adverse Events (AEs)Time frame: Part A (SAD): Up to 405 days; Part B (MAD): Up to 546 days

Locations

9 sites in 5 countries. Site status is shown where the registry gives one.

  • Clinical Trial Site

    Bordeaux, France

  • Clinical Trial Site

    Lyon, France

  • Clinical Trial Site

    Paris, France

  • Clinical Trial Site

    Bonn, Germany

  • Clinical Trial Site

    Haifa, Israel

  • Clinical Trial Site

    Jerusalem, Israel

  • Clinical Trial Site

    Amsterdam, Netherlands

  • Clinical Trial Site

    Birmingham, United Kingdom

  • Clinical Trial Site

    London, United Kingdom

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.